SOURCE: iSonea Ltd.

August 21, 2013 12:51 ET

AsthmaSense® Cloud Earns iSonea Ltd. the 2013 North American Frost & Sullivan Award for New Product Innovation Leadership

SEVERNA PARK, MD--(Marketwired - August 21, 2013) -   AsthmaSense® Cloud, a mobile app that essentially turns a smartphone into an easy-to-use, personal monitoring device for people with asthma, has earned its creator and medical technology company, iSonea Ltd. (ASX: ISN) (OTCQX: ISOAY), the 2013 North American Frost & Sullivan Award for New Product Innovation Leadership.

The 2013 North American Frost & Sullivan Award for New Product Innovation Leadership acknowledges iSonea as a pioneer in the health care industry, specifically mHealth, for its development of body sensing devices that enable self-monitoring for specific health conditions like asthma.

"iSonea is both humbled and honored by this award," said Michael Thomas, iSonea chief executive officer. "To be recognized as a mHealth leader for AsthmaSense Cloud is a testament to the organization's unrelenting commitment to create and commercialize innovative asthma monitoring solutions."

Frost & Sullivan has more than 50 years of experience in working with Global 1000 companies, emerging businesses and the investment community. Each year, they present this award to a company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features of the product and the increased benefit it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

The award will be presented to Thomas at the Frost & Sullivan 2013 Growth, Innovation and Leadership Summit in San Jose, Calif., on September 9.

According to Frost and Sullivan's industry analyst Vin Lee Nim, "In comparison to other competing solutions, adapting iSonea's asthma monitoring technology to the smartphone provides an easier and more convenient means of data collection, analysis and communication. AsthmaSense app and AsthmaSense Cloud's data compilation of users' asthma events clearly illustrate the 'cause and effect' by mapping the lifestyle, environmental and physiological causes of asthma attacks."

The AsthmaSense mobile app turns a smartphone into an easy-to-use, personal monitoring device allowing people with asthma or caregivers to track medication usage, symptoms and triggers accurately. AsthmaSense serves many purposes in the tracking and management of chronic asthma, such as identifying potential risk patterns and trends in asthma symptoms; alerting the user when one should take medication and test his/her asthma risk; and creating a cloud-based network to share one's data with caregivers, physicians and more in a safe and reliable way.

For more information, please visit or

About iSonea Limited:

iSonea Limited (ASX: ISN) (OTCQX: ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is creating a better monitoring system -- enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the United States Food and Drug Administration, the Australian TGA and the European Union. For more information, please visit or

About Frost & Sullivan

For more than 50 years, Frost and Sullivan has developed growth strategies for emerging businesses, the public sector and investment communities. Its Growth Partnership Company collaborates with clients to leverage visionary innovations that address global challenges and related growth opportunities. Its "Growth Partnership" program supports clients by facilitating opportunities that underpin visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavor of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Contact Information